|
Dec 9
|
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
|
|
Dec 8
|
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
|
|
Dec 8
|
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
|
|
Dec 8
|
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
|
|
Dec 8
|
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
|
|
Dec 8
|
Why Viking Therapeutics Was Crushing It This Week
|
|
Dec 7
|
The Zacks Analyst Blog Highlights Alphabet, NVIDIA, Roche, Intuit and AT&T
|
|
Dec 6
|
Top Research Reports for Alphabet, NVIDIA & Roche
|
|
Dec 5
|
UPDATE 3-Merck KGaA suffers major blow as MS drug fails in late-stage trials
|
|
Dec 5
|
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
|
|
Dec 5
|
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
|
|
Dec 5
|
The Fed Is Watching Jobs Data. Why It Should Be Listening to Spotify.
|
|
Dec 5
|
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
|
|
Dec 5
|
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
|
|
Dec 4
|
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
|
|
Dec 4
|
Roche Buys Carmot Therapeutics to Compete in Booming Market for Weight-Loss Drugs
|
|
Dec 4
|
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
|
|
Dec 4
|
Roche: fat fighter drugs buy must precede trial wins
|
|
Dec 4
|
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It’s Hoping to Compete with Eli Lilly, Novo Nordisk.
|
|
Dec 4
|
Roche bets on obesity market with Carmot deal
|